학술논문
Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
Document Type
Report
Author
Doré, Vincent; Doecke, James D.; Saad, Ziad S.; Triana‐Baltzer, Gallen; Slemmon, Randy; Krishnadas, Natasha; Bourgeat, Pierrick; Huang, Kun; Burnham, Samantha; Fowler, Christopher; Rainey‐Smith, Stephanie R.; Bush, Ashley I.; Ward, Larry; Robertson, Jo; Martins, Ralph N.; Masters, Colin L.; Villemagne, Victor L.; Fripp, Jurgen; Kolb, Hartmuth C.; Rowe, Christopher C.
Source
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. April 2022, Vol. 14 Issue 1
Subject
Language
English
Abstract
INTRODUCTION Assessing brain levels of amyloid beta (Aβ) plaque and tau aggregation has a central role in the selection of individuals for clinical trials and assessing the efficacy of therapeutic [...]
: Introduction: We evaluated a new Simoa plasma assay for phosphorylated tau (P‐tau) at aa217 enhanced by additional p‐tau sites (p217+tau). Methods: Plasma p217+tau levels were compared to [sup.18]F‐NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and [sup.18]F‐MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU) participants. Results: Compared to Aβ− CU, the plasma levels of p217+tau increased 2‐fold in Aβ+ CU and 3.5‐fold in Aβ+ CI. In Aβ− the p217+tau levels did not differ significantly between CU and CI. P217+tau correlated with Aβ centiloids P =.67 (CI, P =.64; CU, P =.45) and tau SUVR[sub.MT] P =.63 (CI, P =.69; CU, P =.34). Area under curve (AUC) for Alzheimer's disease (AD) dementia versus Aβ− CU was 0.94, for AD dementia versus other dementia was 0.93, for Aβ+ versus Aβ− PET was 0.89, and for tau+ versus tau− PET was 0.89. Discussion: Plasma p217+tau levels elevate early in the AD continuum and correlate well with Aβ and tau PET.
: Introduction: We evaluated a new Simoa plasma assay for phosphorylated tau (P‐tau) at aa217 enhanced by additional p‐tau sites (p217+tau). Methods: Plasma p217+tau levels were compared to [sup.18]F‐NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and [sup.18]F‐MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU) participants. Results: Compared to Aβ− CU, the plasma levels of p217+tau increased 2‐fold in Aβ+ CU and 3.5‐fold in Aβ+ CI. In Aβ− the p217+tau levels did not differ significantly between CU and CI. P217+tau correlated with Aβ centiloids P =.67 (CI, P =.64; CU, P =.45) and tau SUVR[sub.MT] P =.63 (CI, P =.69; CU, P =.34). Area under curve (AUC) for Alzheimer's disease (AD) dementia versus Aβ− CU was 0.94, for AD dementia versus other dementia was 0.93, for Aβ+ versus Aβ− PET was 0.89, and for tau+ versus tau− PET was 0.89. Discussion: Plasma p217+tau levels elevate early in the AD continuum and correlate well with Aβ and tau PET.